2 completed, 1 active not recruiting, 1 not yet recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
Follow Unresectable Cholangiocarcinoma: new trials by email Literature Review of Unresectable Cholangiocarcinoma trials Research Report on Unresectable Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy Pemigatinib - Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Incyte Corporation | 72 | 2026-12-15 | 2026-10-20 |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Carboplatin, Paclitaxel, Pevonedistat - Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2020-03-16 | 2026-10-26 |
| Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Atezolizumab, Biopsy, Biospecimen Collection - Gallbladder Carcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2018-02-08 | 2024-04-05 |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Entinostat, Nivolumab - Metastatic Cholangiocarcinoma, Cholangiocarcinoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 44 | 2017-11-06 | 2025-05-28 |
Cholangiocarcinoma (4) · Carcinoma, Hepatocellular (1) · Gallbladder Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Adenocarcinoma (4) · Carcinoma (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms by Site (3) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gallbladder Diseases (1) · Liver Diseases (1) · Liver Neoplasms (1)
Biopsy (1) · Carboplatin (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Paclitaxel (1) · Specimen Handling (1) · Taxes (1) · atezolizumab (1) · cobimetinib (1) · entinostat (1) · pemigatinib (1) · pevonedistat (1)
National Cancer Institute (NCI) (2) · Incyte Corporation (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (3)
Dustin A Deming (1) · Nilofer Azad, MD (1) · Nilofer S Azad (1)
PMID 34907910, PMID 39532835, PMID 39932259
2025 (1), P01CA247886 (1), U10CA180820 (1), UM1CA186691 (1)